Litcius/Paper detail

Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention

Jadwiga Maniewska, Dagmara Jeżewska

2021Cancers78 citationsDOIOpen Access PDF

Abstract

Since colorectal cancer is one of the world’s most common cancers, studies on its prevention and early diagnosis are an emerging area of clinical oncology these days. For this study, a review of randomized controlled, double-blind clinical trials of selected NSAIDs (aspirin, sulindac and celecoxib) in chemoprevention of colorectal cancer was conducted. The main molecular anticancer activity of NSAIDs is thought to be a suppression of prostaglandin E2 synthesis via cyclooxygenase-2 inhibition, which causes a decrease in tumor cell proliferation, angiogenesis, and increases apoptosis. The lower incidence of colorectal cancer in the NSAID patients suggests the long-lasting chemopreventive effect of drugs studied. This new approach to therapy of colorectal cancer may transform the disease from a terminal to a chronic one that can be taken under control.

Topics & Concepts

MedicineCelecoxibColorectal cancerSulindacAspirinCancerAngiogenesisClinical trialCyclooxygenaseInternal medicineCancer preventionOncologyPharmacologyNonsteroidalBiochemistryChemistryEnzymeInflammatory mediators and NSAID effectsCancer, Stress, Anesthesia, and Immune ResponseEstrogen and related hormone effects
Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention | Litcius